Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03929718 · ClinicalTrials.gov registry record · Early Phase 1
Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation
A Early Phase 1 study of Afib, sponsored by Piedmont Healthcare.
- Active
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT03929718: Active Early Phase 1 study of Afib, sponsored by Piedmont Healthcare.
NCT03929718 is a Early Phase 1 study of Afib that is active but no longer recruiting, run by Piedmont Healthcare. The registered enrollment target is 50 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03929718, a Early Phase 1 study of Afib, is active but no longer recruiting, sponsored by Piedmont Healthcare.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to accurately determine, using an implantable rhythm monitor, the long-term incidence of new atrial fibrillation after ablation of atrial flutter in those treated with spironolactone compared with standard medical therapy.
Primary Outcome
1\. To accurately determine the long-term incidence of new-onset AF after CTI ablation using an implantable rhythm monitor
Conditions Studied
Interventions
- DRUG Spironolactone
- DRUG No Spironolactone
Study Locations (1)
Georgia
- Piedmont Heart Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-04-24 |
| Est. Completion | 2027-09 |
| Phase | Early Phase 1 |
What the registry record for NCT03929718 still lists
NCT03929718 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Afib appearing as the primary indexed condition, and to 2 interventions - of which Spironolactone is the first listed.
NCT03929718 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT03929718 about?
NCT03929718 is a clinical study titled "Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation". The purpose of this study is to accurately determine, using an implantable rhythm monitor, the long-term incidence of new atrial fibrillation after ablation of atrial flutter in those treated with spironolactone compared with standard medical therapy.
What is the current status of trial NCT03929718?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2019-04-24. Estimated completion is 2027-09.
What conditions does trial NCT03929718 study?
This clinical trial studies the following conditions: Afib.
What interventions are being tested in trial NCT03929718?
The interventions under investigation include: Spironolactone (DRUG), No Spironolactone (DRUG).
Who is sponsoring clinical trial NCT03929718?
This trial is sponsored by Piedmont Healthcare, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03929718 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Afib
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03929718's enrollment target sits among peer trials
50 493rd of 2000 higher than 1,468 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI